Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Arteaus Therapeutics

- PMLiVE

Matt Kiely appointed as Genmab General Manager in the UK

Matt brings more than 20 years of global pharmaceutical leadership

- PMLiVE

FDA approves Teva’s Ajovy to prevent episodic migraine in paediatric patients

One in ten children and adolescents in the US are affected by the neurological condition

- PMLiVE

AbbVie/Genmab’s lymphoma drug shows promise in phase 3 combination trial

Follicular lymphoma affects around 15,000 people in the US every year

- PMLiVE

Rain Free Days: A Migraine App Shaped by Real Experiences

Rain Free Days® is a free migraine support app created by Teva, 11 London, and the migraine community. It helps users track symptoms, spot patterns, and access personalised resources like...

11 London

EU flag

Genmab announces EC approval of Tivdak in recurrent or metastatic cervical cancer

Approximately 660,000 new cases of the disease were diagnosed globally in 2022 alone

- PMLiVE

AbbVie/Genmab’s Epkinly granted FDA accelerated approval to treat follicular lymphoma

Approximately 15,000 people develop the form of non-Hodgkin lymphoma every year in the US

- PMLiVE

Pfizer/Genmab’s Tivdak granted full FDA approval for recurrent or metastatic cervical cancer

It is estimated that more than 13,960 new cases of invasive cervical cancer were diagnosed in the US last year

- PMLiVE

Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition

The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours

- PMLiVE

Seagen and Genmab’s Tivdak shows promise in phase 3 cervical cancer trial

The drug received FDA accelerated approval in 2021 to treat patients with advanced disease

- PMLiVE

AbbVie and Genmab’s blood cancer therapy granted FDA accelerated approval

Approximately 150,000 new cases of DLBCL are diagnosed globally each year

- PMLiVE

Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray

Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired

- PMLiVE

Pfizer to acquire Biohaven in deal worth over $11bn

The deal will expand Pfizer’s Internal Medicine pipeline

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links